BBA Clinical Diagnostic Lab Test Negotiated Rulemaking To Begin July 13
This article was originally published in The Gray Sheet
Clinical diagnostic laboratory tests whose medical utility or clinical effectiveness is considered "controversial" will be among the specific types of tests for which national coverage policies are to be developed through negotiated rulemaking, the Health Care Financing Administration says in a June 3 Federal Register notice.
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.